Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
U-CH3 is a small molecule ureido-substituted benzene sulfonamide (USB) that acts as a potent and selective inhibitor of the tumor-associated carbonic anhydrase isoforms IX (CA IX) and XII (CA XII). It functions by binding to the catalytic zinc ion within the enzyme's active site via its sulfonamide moiety and interacting with a "selective pocket" (specifically residue 131), which provides significant selectivity over the off-target cytosolic isoform CA II. In preclinical breast cancer models, U-CH3 has demonstrated the ability to inhibit cell growth, migration, and invasion, particularly in triple-negative breast cancer (TNBC) and ER-positive cell lines. Research indicates a notable disconnect between its high affinity for purified recombinant proteins and the significantly higher concentrations required to achieve growth inhibition in intact cells, suggesting that its anti-proliferative effects may involve mechanisms beyond simple exofacial CA inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on U-CH3.